Tatsuhiro Sato, Ken Akao, Ayuko Sato, Tohru Tsujimura, Satomi Mukai, Yoshitaka Sekido. Aberrant expression of NPPB through YAP1 and TAZ activation in mesothelioma with Hippo pathway gene alterations. Cancer medicine. 2023. 12. 12. 13586-13598
Yoshitaka Sekido, Tatsuhiro Sato. NF2 alteration in mesothelioma. Frontiers in Toxicology. 2023. 5
Koya Suzuki, Masaki Tange, Ryota Yamagishi, Hiroyuki Hanada, Satomi Mukai, Tatsuhiro Sato, Takeshi Tanaka, Tomohiro Akashi, Kenji Kadomatsu, Tohru Maeda, et al. SMG6 regulates DNA damage and cell survival in Hippo pathway kinase LATS2-inactivated malignant mesothelioma. Cell Death Discovery. 2022. 8. 1
Tatsuhiro Sato, Hayao Nakanishi, Ken Akao, Maho Okuda, Satomi Mukai, Tohru Kiyono, Yoshitaka Sekido. Three newly established immortalized mesothelial cell lines exhibit morphological phenotypes corresponding to malignant mesothelioma epithelioid, intermediate, and sarcomatoid types, respectively. Cancer cell international. 2021. 21. 1. 546-546
Yuta Kodama, Ichidai Tanaka, Tatsuhiro Sato, Kazumi Hori, Soei Gen, Masahiro Morise, Daisuke Matsubara, Mitsuo Sato, Yoshitaka Sekido, Naozumi Hashimoto. Oxytocin receptor is a promising therapeutic target of malignant mesothelioma. Cancer science. 2021. 112. 9. 3520-3532